本文關(guān)鍵詞： 血府逐瘀湯 肝纖維化 瘀血阻絡(luò)證 臨床觀察　出處：《長春中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:通過與復(fù)方鱉甲軟肝片的研究比較,觀察血府逐瘀湯加味治療慢性乙型肝炎肝纖維化(瘀血阻絡(luò)證)的臨床療效。方法:將來自長春中醫(yī)藥大學(xué)附屬醫(yī)院肝脾胃病科門診符合慢性乙型肝炎肝纖維化(瘀血阻絡(luò)證)臨床診斷的患者共72位,按1:1的比例采用隨機(jī)對照方法,隨機(jī)分為2組,治療組36例,對照組36例。治療組給予血府逐瘀湯加味(由桃仁,紅花,川芎,大黃等藥物組成),對照組給予復(fù)方鱉甲軟肝片,兩組療程均為24周。觀察并記錄兩組患者治療前后中醫(yī)癥狀積分、血清肝纖維化標(biāo)志物(HA、LN、IV-C、PC-Ⅲ)及肝功能指標(biāo),進(jìn)行統(tǒng)計(jì)學(xué)分析比較。結(jié)果:(1)中醫(yī)證侯療效評價(jià),治療組30例中,顯效、有效分別為11例、16例,總有效率為90.00%;對照組30例中,顯效、有效分別為5例,13例,總有效率為60.00%。治療組和對照組總有效率比較~△P0.05。(2)經(jīng)統(tǒng)計(jì)學(xué)比較,治療前兩組肝功能指標(biāo)無明顯差異,P0.05,具有可比性。治療結(jié)束后兩組肝功能指標(biāo)均有改善,治療組與本組治療前比較*P0.05,治療組改善更明顯,與對照組治療后比較▲P0.05,具有顯著性差異。(3)經(jīng)統(tǒng)計(jì)學(xué)比較,兩組在治療前肝纖維化指標(biāo)無明顯差異,P0.05,具有可比性。治療結(jié)束后兩組血清肝纖維化指標(biāo)均有改善,治療組與本組治療前比較*P0.05,與對照組治療后比較▲P0.05,具有顯著性差異。(4)抗肝纖維化綜合療效比較,治療組,顯效7例,有效19例,總有效率86.67%,對照組,顯效4例,有效13例,總有效率56.67%,治療組與對照組總有效率比較~△P0.05,具有顯著性差異。結(jié)論:由以上數(shù)據(jù)可得出,治療組明顯優(yōu)于對照組。表明血府逐瘀湯加味治療慢性乙型肝炎肝纖維化(瘀血阻絡(luò)證)可明顯改善患者脅痛、腹脹等癥狀,修復(fù)受損肝細(xì)胞,改善肝纖維化病變程度,提高患者生存質(zhì)量,為日后臨床科學(xué)、合理用藥提供依據(jù),進(jìn)一步豐富了中醫(yī)藥理論治療肝纖維化的內(nèi)涵。
[Abstract]:Objective: to compare the results with compound Biejia Ruangan tablets. To observe the clinical effect of Xuefu Zhuyu decoction on chronic hepatitis B liver fibrosis (blood stasis obstruction of collaterals). Methods: the outpatient department of liver and spleen gastropathy, affiliated hospital of Changchun University of traditional Chinese Medicine, was in accordance with chronic hepatitis B liver fibrosis. There were 72 patients (blood stasis and obstruction of collaterals) clinically diagnosed. According to the ratio of 1: 1, randomly divided into two groups, 36 cases in the treatment group and 36 cases in the control group. The treatment group was given Xuefu Zhuyu decoction (composed of peach kernel, safflower, Chuanxiong, rhubarb, etc.) and the control group was given compound Biejia Ruanggan tablets. The course of treatment in both groups was 24 weeks. The scores of TCM symptoms, serum markers of hepatic fibrosis (HALNNX IV-C- 鈪，

本文編號：1513150